Healthcare Dec 31, 2021 01:55 PM (GMT+8) · EqualOcean
Samsung biology announced in the Korean stock exchange on December 30 that the report that "Samsung Group will acquire Bojian, an American biopharmaceutical company, with 50 trillion won" is untrue. Samsung and Biogen jointly invested in the establishment of Samsung bioepis company in 2012, with Samsung holding 51% and Bogen holding 49%.